One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial

JAMA

Volumn 307, Issue 12, 2012, Pages 1265-1272

  Joensuu, Heikki ^a   Eriksson, Mikael ^b   Hall, Kirsten Sundby ^d   Hartmann, Jörg T ^e   Pink, Daniel ^f   Schütte, Jochen ^g   Ramadori, Giuliano ^h   Hohenberger, Peter ⁱ   Duyster, Justus ^j   Al Batran, Salah Eddin ^k   Schlemmer, Marcus ^l   Bauer, Sebastian ^m   Wardelmann, Eva ⁿ   Sarlomo Rikala, Maarit ^a   Nilsson, Bengt ^o   Sihto, Harri ^p   Monge, Odd R ^q   Bono, Petri ^a   Kallio, Raija ^r   Vehtari, Aki ^s   Leinonen, Mika ^t   Alvegar̊d, Thor ^c   Reichardt, Peter ^f   more..

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f HELIOS KLINIKUM BERLIN BUCH   (Germany)

^g MARIEN HOSPITAL DÜSSELDORF   (Germany)

^h UNIVERSITY OF GÖTTINGEN   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k KRANKENHAUS NORDWEST   (Germany)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁿ UNIVERSITY OF COLOGNE   (Germany)

^o SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^p UNIVERSITY OF HELSINKI   (Finland)

^q HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^r OULU UNIVERSITY HOSPITAL   (Finland)

^s AALTO UNIVERSITY   (Finland)

^t Pharma Ltd   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HEART FAILURE; HEART INFARCTION; HUMAN; KIT GENE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG EDEMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; MUTATIONAL ANALYSIS; MUTATOR GENE; NAUSEA; OVERALL SURVIVAL; PERIORBITAL EDEMA; PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA GENE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; GASTROINTESTINAL TUMOR; GENETICS; MIDDLE AGED; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859187987     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.347     Document Type: Article

References (28)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83. (Pubitemid 44692418)
2. Woodall CE III, Brock GN, Fan J, et al. An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system. Arch Surg. 2009;144 (7):670-678.
3. Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors: a population-based study. BMC Cancer. 2007;7:230.
4. Nilsson B, Bümming P, Meis-Kindblom J-M, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era: a population-based study in western Sweden. Cancer. 2005;103(4):821-829. (Pubitemid 40216412)
5. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007;369(9574):1731-1741. (Pubitemid 46778870)
6. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37(12):1527- 1535. (Pubitemid 44792229)
7. Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31(1):113-120. (Pubitemid 46036910)
8. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459-465. (Pubitemid 34747864)
9. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008; 39(10):1411-1419.
10. Gold JS, Gönen M, Gutiérrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10(11):1045-1052.
11. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-1134. (Pubitemid 39296599)
12. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4):620-625. (Pubitemid 351264357)
13. Dematteo RP, Ballman KV, Antonescu CR, et al; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669):1097-1104.
14. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
15. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743-1749.
16. Andersson J, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130(6):1573-1581. (Pubitemid 43668833)
17. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis based on pooled population-based cohorts. Lancet Oncol. 2012;13(3):265-274.
18. Takahashi T, Nakajima K, Nishitani A, et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12(5): 369-374. (Pubitemid 47573418)
19. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14(7):2018-2027. (Pubitemid 46988258)
20. Hohenberger P, Ronellenfitsch U, Oladeji O, et al. Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010; 97(12):1854-1859.
21. Reichardt R, Haartmann JT, Sundby Hall K, et al. Response toimatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment: the first analysis in the SSGXVIII/AIO trial patient population [abstract]. Eur J Cancer. 2011;47(suppl 2):15.
22. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112(3):608-615. (Pubitemid 351186201)
23. Gal R, Rath-Wolfson L, Rosenblatt Y, Halpern M, Schwartz A, Koren R. An improved technique for mitosis counting. Int J Surg Pathol. 2005;13(2):161-165. (Pubitemid 40617544)
24. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908-916. (Pubitemid 44175142)
25. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010;116(1):184-192.
26. Debiec-Rychter M, Sciot R, Le Cesne A, et al; EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42(8):1093-1103. (Pubitemid 44275331)
27. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342-4349. (Pubitemid 46621810)
28. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25(9):1107-1113. (Pubitemid 46596763)